mTOR Inhibitors as Radiosensitizers in Neuroendocrine Neoplasms

Peptide receptor radioligand therapy (PRRT) has evolved as an important second-line treatment option in the management of inoperable and metastatic neuroendocrine neoplasms (NEN). Though high radiation doses can be delivered to the tumors, complete remission is still rare. Radiosensitization prior t...

Descripción completa

Detalles Bibliográficos
Autores principales: Exner, Samantha, Arrey, Gerard, Prasad, Vikas, Grötzinger, Carsten
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2021
Materias:
Oncology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7897674/
https://www.ncbi.nlm.nih.gov/pubmed/33628728
http://dx.doi.org/10.3389/fonc.2020.578380

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7897674/
https://www.ncbi.nlm.nih.gov/pubmed/33628728
http://dx.doi.org/10.3389/fonc.2020.578380

Ejemplares similares